All In Biotech

Free tool

FAERS Monitor: Zituvimet Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216778 or its brand name (Zituvimet Xr, Metformin Hydrochloride, Sitagliptin). Reports on generic versions are filed under their own applications.

Reports

42

Serious

28

67% of reports

Hospitalization

11

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective6
  • completed suicide4
  • dizziness4
  • nausea4
  • pain in extremity4
  • abnormal dreams3
  • diarrhoea3
  • malaise3
  • somnolence3
  • abdominal pain2
  • anxiety2
  • blood bilirubin increased2
  • blood creatinine increased2
  • blood glucose increased2
  • decreased appetite2

Reports by year received

View as table
YearReports
20103
201113
201221
20251
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,117 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abnormal dreamsSignal354.418.3109
blood bilirubin increased237.19.639
completed suicideSignal424.09.567
blood creatinine increased215.34.014
somnolenceSignal37.52.511
pain in extremitySignal46.82.715
blood glucose increased25.31.43
decreased appetite24.31.12
abdominal pain24.31.12
dizzinessSignal44.01.66
anxiety23.50.92
malaise33.41.23
nausea42.51.02
diarrhoea32.30.81
drug ineffective62.31.13

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.